These innovative compounds represent a significant leap in the therapy of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates promising efficacy in reducing blood glucose levels. https://kathrynnfjq910574.thenerdsblog.com/45154661/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide